Introduction
============

*Salmonella* species (*Salmonella* spp.) are a group of bacteria that can survive in animals, human beings, and the environment. They can cause from mild to life-threatening sal-monellosis, such as enteritis and typhoid fever, both in human beings and animals, and have become a major public health issue worldwide.[@b1-idr-11-267] Of \>2,000 *Salmonella* serotypes, \<100 serotypes account for most of prevalent and important human infections, including *Salmonella* Typhi (*S*. typhi), *Salmonella* Enteritidis (*S*. Enteritidis), and *Salmonella* Typhimurium (*S*. Typhimurium).[@b2-idr-11-267],[@b3-idr-11-267]

Quinolones are a family of synthetic broad-spectrum antimicrobial drugs.[@b4-idr-11-267] The first quinolone is nalidixic acid, which is considered to be the predecessor of all members of the quinolone family. The majority of quinolones in present clinical use are more powerful fluoroquinolones, such as ciprofloxacin (CIP), which remains the first-line drug of choice for treating salmonellosis.[@b5-idr-11-267]

Quinolone resistance in *Salmonella* spp. is an increasing problem.[@b6-idr-11-267] Based on susceptibility testing results of nalidixic acid and CIP, quinolone resistance can be ranked at three levels: resistant to CIP (resistant to both drugs), of reduced CIP susceptibility (resistant to nalidixic acid and intermediate to CIP), and susceptible to both drugs.[@b7-idr-11-267] Recently, particular concern has been raised about highly CIP-resistant strains of several *Salmonella* serotypes circulating in both human beings and the environment.[@b8-idr-11-267],[@b9-idr-11-267] To treat salmonellosis cases caused by CIP-resistant *Salmonella* strains, a third-generation cephalosporin, such as cefotaxime or ceftriaxone, is the first choice.[@b10-idr-11-267]

CIP resistance in *Salmonella* is considered to be mainly attributed to point mutations in *gyrA*, *gyrB*, and *parC* in the quinolone resistance-determining regions (QRDRs).[@b11-idr-11-267] In addition, transferable plasmid-mediated quinolone resistance (PMQR) genes may cause low-level resistance to fluoroquinolones.[@b11-idr-11-267] These genes include pentapeptide repeat protein-encoding *qnrA*, *qnrB*, and *qnrS*; an efflux-pump-encoding *qepA*; and an aminoglycoside acetyltransferase-encoding enzyme variant *aac(6′)-Ib-cr*.[@b12-idr-11-267],[@b13-idr-11-267]

A lot of studies have been conducted to explore CIP-resistant *Salmonella* strains of several particular serotypes. Most of these studies are some kind of "case report analysis" with limited information on overall quinolone resistance in *Salmonella* species. There are several factors making quinolone resistance complex in *Salmonella*, including \>2,000 different *Salmonella* serotypes, a variety of hosts for *Salmonella*, and wide use of quinolones in human beings and animals. This situation calls for a more general conclusion for explaining CIP resistance development in *Salmonella* species as a whole.

Therefore, through investigating the development of quinolone resistance in all *Salmonella* species, what serotypes account for most CIP-resistant isolates, and the relevant molecular mechanisms, we aimed to obtain an overview of development of quinolone resistance and the relevant molecular mechanisms in *Salmonella*.

Materials and methods
=====================

Bacterial isolates
------------------

A total of 1,776 *Salmonella* isolates, 1,226 from non-duplicate patient specimens (1,006 feces and 220 blood samples) and 550 from environmental samples (445 food samples and 105 river water samples), were collected in Ningbo, a city in mid-east China that has a population of 9 million and a land area of 9,780 km^2^, between 2005 and 2016 ([Table 1](#t1-idr-11-267){ref-type="table"}). These isolates were from an enteric disease surveillance project and clinical patients. Approval of clinical isolates from the ethics committee of Ningbo No. 2 Hospital, Zhejiang, China, and written informed consent of patients were obtained. These isolates were identified by API 20E biochemical identification system (bioMerieux, Paris, France) and were typed into 51 serotypes using *Salmonella*-specific antisera (Denka Seiken, Japan). In Ningbo, the top three most found serotypes were *S*. typhi (188 isolates), *S*. Enteritidis (163 isolates), and *S*. Typhimurium (156 isolates). All *S*. typhi isolates came from patients. *S*. Typhimurium and S. Enteritidis isolates came from both patients and environmental sources.

Antimicrobial susceptibility testing (AST)
------------------------------------------

Since comparative study has proved high categorical agreements between E-test and disk diffusion and broth microdilution for the detection of fluoroquinolone resistance in typhoidal and nontyphoidal *Salmonella* serotypes,[@b14-idr-11-267] to screen for quinolone-resistant isolates, we performed AST on all isolates using the disk diffusion method specified in Clinical and Laboratory Standards Institute (CLSI) document M02-A12.[@b15-idr-11-267] AST results were interpreted according to guidelines in CLSI document M100-S27.[@b16-idr-11-267] The antibiotic disks (Oxoid, Hampshire, UK) included CIP (5 μg) and nalidixic acid (30 μg), as well as ampicillin (10 μg), cefotaxime (30 μg), cefotaxime--clavulanate (30/10 μg), gentamicin (10 μg), chloramphenicol (30 μg), and trimethoprim--sulfamethoxazole (1.25/23.75 μg). *Escherichia coli* ATCC 25922 was used as a quality control strain. Isolates with ≥5 mm increase in the zone diameter for cefotaxime--clavulanate vs. the zone diameter for cefotaxime were defined to be producing extended-spectrum β-lactamase (ESBL). Then, minimal inhibitory concentrations (MICs) of CIP and cefotaxime in CIP-resistant isolates were determined using the E-test (Oxoid) method. MICs of nalidixic acid in CIP-resistant isolates were determined using broth microdilution. Based on AST results, isolates were classified into three groups with different CIP resistance levels: susceptibility, reduced CIP susceptibility, and resistance to CIP.

Detection of genetic determinants associated with quinolone and β-lactam resistance
-----------------------------------------------------------------------------------

CIP-resistant isolates, 100 randomly selected reduced CIP-susceptible isolates, and 100 randomly selected CIP-susceptible isolates were tested for genes related to quinolone resistance using primers previously described ([Table 2](#t2-idr-11-267){ref-type="table"}), including *gyrA*, *gyrB*, and *parC*; PMQR genes *qnrA*, *qnrB*, and *qnrS*; efflux-pump-encoding *qepA*; and aminoglycoside acetyltransferase-encoding enzyme variant *aac(6′)-Ib-cr*. Amplified sequences of *gyr* and *parC* were sequenced (Thermo Fisher Scientific, Waltham, MA, USA) and their mutations were determined by aligning against the homologous sequence of *S*. Typhimurium LT2. Additionally, CIP- and β-lactam-resistant isolates were tested for reported β-lactamase genes (*bla*~CTX-M-like~, *bla*~TEM~, and *bla*~OXA~).

Pulsed-field gel electrophoresis (PFGE)
---------------------------------------

CIP-resistant isolates were subtyped by PFGE using restriction enzyme *XbaI* following PulseNet standardized protocol.[@b19-idr-11-267] *Salmonella* Braenderup (H9812) was used as a reference strain. The PFGE patterns were determined by BioNumerics software (Applied Maths, Sint-Martens-Latum, Belgium). A dendrogram of PFGE patterns was constructed using the unweighted pair-group method with arithmetic mean (UPGMA) with a position tolerance of 1.2%. PFGE patterns were defined by groups of bands that formed at least 90% Dice similarity cutoffs on the dendrogram. In this study, a cluster was defined as more than one isolate with identical PFGE patterns. Sporadic cases were defined when there was a unique PFGE pattern for one isolate.

Interpretation of results for overall quinolone resistance
----------------------------------------------------------

We assessed overall quinolone resistance in *Salmonella* species as follows. First, levels of quinolone resistance in the three most common serotypes, *S*. typhi, *S*. Typhimurium, and *S*. Enteritidis, were derived for different isolation periods. Second, what serotypes accounted for, and what PFGE features were found in, highly quinolone-resistant isolates that were resistant to CIP and nalidixic acid, were assessed. Third, what genes related to quinolone resistance existed in quinolone-resistant isolates.

We used SPSS 20 software to calculate Pearson's chi-squared test for comparison of resistance rates between different groups of isolates. Statistical significance was accepted at *P* value of \<0.05.

Results
=======

Totally, of 1,776 isolates, 26 (1.5%) were resistant to CIP and 522 (29%) were of reduced CIP susceptibility ([Table 3](#t3-idr-11-267){ref-type="table"}). The three most common *Salmonella* serotypes were *S*. typhi, *S*. Enteritidis, and *S*. Typhimurium; each had distinct features of quinolone resistance development during three periods from 2005 to 2016 ([Table 1](#t1-idr-11-267){ref-type="table"}). During the three periods of 2005--2008, 2009--2012, and 2013--2016, S. typhi was characteristic of apparent increase in reduced CIP susceptibility: from 9% (5/54) to a moderate level of 35% (21/60) and a high rate of 89% (66/74); *S*. Enteritidis remained at steady, high rates of reduced CIP susceptibility: 59% (23/39), 56% (41/73), and 67% (34/51); in contrast, *S*. Typhimurium showed both a high level of reduced CIP susceptibility, i.e., 44% (17/39), 35% (16/46), and 38% (27/71), and a prevalence of 5% of CIP resistance. Overall, CIP resistance was found in nine of 51 serotypes: Derby, London, Kentucky, Indiana, Corvallis, Rissen, Hadar, Typhimurium, and Agona. Especially, six *Salmonella* Indiana (*S*. Indiana) isolates were resistant to CIP. The MIC values were at three levels in CIP-resistant isolates: 2--4 μg/mL (seven serotypes except for Kentucky and Indiana), 16 μg/mL (one Kentucky isolate), and \>32 μg/mL (all Indiana isolates; [Table 4](#t4-idr-11-267){ref-type="table"}).

As to other antimicrobial agents, prevalence of resistance (33.8%) to ampicillin was the highest ([Table 3](#t3-idr-11-267){ref-type="table"}). Average prevalence of resistance to other antimicrobials was significantly higher in the group of CIP-resistant isolates than in the other two groups (*P*\<0.01). Of 26 CIP-resistant isolates, all were concurrently resistant to ampicillin and 21 were also concurrently resistant to cefotaxime and produced ESBL. In addition, 19 CIP-resistant isolates were from patients and seven were from environmental sources. All *S*. Indiana CIP-resistant isolates and a number of *S*. Typhimurium, *S*. Agona, and S. Rissen CIP-resistant isolates were from environmental sources ([Figure 1](#f1-idr-11-267){ref-type="fig"}).

There were two types of *gyrA* mutations at loci 83, three types of *gyrA* mutations at loci 87, and four PMQR genes detected in CIP-resistant and reduced CIP-susceptible isolates ([Tables 4](#t4-idr-11-267){ref-type="table"} and [5](#t5-idr-11-267){ref-type="table"}). Most found *gyrA* mutations were S83F and D87N that could be detected in both groups of isolates. A silent mutation S(TCC)83S(TCT) was found in a number of CIP-resistant Agona and Derby isolates. It is important to note that, most reduced CIP-susceptible *S*. typhi had S83F or D87Y mutation. Especially, this D87Y mutation was detected only in reduced CIP-susceptible *S*. typhi. No *gyrB* mutation was found in such reduced CIP-susceptible *S*. typhi isolates. Regarding PMQR genes, 100% CIP-resistant isolates harbored *qnrB* that, in contrast, could not be detected in reduced CIP-susceptible isolates. Gene *aac(6′)-Ib-cr* in CIP-resistant isolates was also detected at a much higher prevalence in CIP-resistant isolates. *qnrS* existed in both groups. Especially, in Kentucky and Indiana isolates with CIP MIC of \>16 μg/mL, two *gyrA* mutations, *qnrB* and usually *aac(6′)-Ib-cr*, concurrently existed. In isolates of other serotypes with smaller CIP MIC, one or no *gyrA* mutation and at least *qnrB* and sometimes plus *aac(6′)-Ib-cr* existed. No genetic determinants of quinolone resistance were detected in 100 susceptible isolates.

As to β-lactam resistance genes in 26 β-lactam- and CIP-resistant isolates, 21 were detected positive for at least one of TEM, OXA, and CTX-M genes ([Table 4](#t4-idr-11-267){ref-type="table"}).

PFGE results
------------

Although there was no overall clustering in 23 (three failed PFGE) CIP-resistant isolates, PFGE results showed that highly identical PFGE patterns were observed in some common serotypes, such as Typhimurium and Indiana, indicating that CIP-resistant isolates of some serotypes had very limited diversity ([Figure 1](#f1-idr-11-267){ref-type="fig"}).

Discussion
==========

We found distinctive features about the overall development of quinolone resistance in *Salmonella* species: high prevalence of reduced CIP susceptibility and low prevalence of CIP resistance, which focuses on several serotypes, and PMQR gene *qnrB* being the most common indicator for CIP resistance.

Totally, the ratio for three levels of quinolone susceptibility (CIP resistant:reduced CIP susceptible:CIP susceptible) was 26:522:1,228, indicating a small proportion of CIP-resistant isolates and large proportion of reduced CIP-susceptible isolates. In the literature, a few studies have explored overall CIP resistance development in *Salmonella* and the limited results are varied. In Hong Kong, a study showed that 42% of 963 non-typhoidal *Salmonella* isolates are resistant to nalidixic acid (corresponding to reduced CIP susceptibility in our study) and 13.7% are resistant to CIP,[@b6-idr-11-267] whereas the National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS) found that, of 2,236 non-typhoidal *Salmonella* isolates, only 56 (2%) are resistant to nalidixic acid and eight (0.4%) are resistant to CIP.[@b20-idr-11-267] Our results are distinct from the Hong Kong study that shows a high prevalence of both CIP resistance and reduced CIP susceptibility, and the NARMS report that shows a low prevalence of both. A recent study has reported that 16.9% of isolates of animal sources are resistant to CIP, a prevalence much higher than that (1.5%) in our study. This difference suggests a gap in CIP resistance level between isolates from animals and human beings.[@b21-idr-11-267]

Our results show distinctive phenotypes of quinolone resistance in different serotypes. As to the three most common serotypes, *S*. typhi showed quickly increased prevalence of reduced CIP susceptibility in recent years, a finding that we have reported in a previous study.[@b22-idr-11-267] *S*. Enteritidis remained at a high prevalence of reduced CIP susceptibility throughout the study period. Nevertheless, in addition to a high prevalence of reduced CIP susceptibility, 5% of S. Typhimurium isolates were resistant to CIP. As early as 2005, up to 70% of 44 *S*. Typhimurium isolates from outpatients were reported to be resistant to CIP.[@b23-idr-11-267] However, our findings illustrate that CIP resistance in *S*. Typhimurium has emerged only during recent years. In our study, the most serious situation of CIP resistance was observed in *S*. Indiana, a result consistent with a recent report.[@b24-idr-11-267]

CIP resistance was found centrally in limited serotypes. PFGE results of CIP-resistant isolates show no overall clustering and a predominant clone in several serotypes, as indicated by limited diversity among multiple isolates of one serotype ([Figure 1](#f1-idr-11-267){ref-type="fig"}).

In our study, CIP resistance usually exists along with β-lactam resistance and ESBL production in the nine serotypes. Although there were several studies demonstrating concurrent resistance to CIP and cefotaxime in a particular serotype,[@b25-idr-11-267]--[@b27-idr-11-267] due to the fact that these studies involved only one serotype, it is difficult to answer whether the concurrent resistance is mainly in a particular serotype or a strain or is a general case. This phenomenon proves that concurrent resistance to CIP and β-lactam is more a general phenomenon.

Finally, while analyzing the molecular mechanisms of resistance to CIP, the most interesting finding was that, rather than the commonly considered *gyrA* mutations, a type of PMQR structure *qnrB* is the most common indicator for CIP resistance because it was only found in all CIP-resistant isolates ([Tables 4](#t4-idr-11-267){ref-type="table"} and [5](#t5-idr-11-267){ref-type="table"}). The second most common indicator is *aac(6′)-Ib-cr*. In contrast, *gyrA* mutations are not necessarily the cause of CIP resistance since these mutations were often found in reduced CIP-susceptible isolates and were not found in a number of CIP-resistant isolates. Especially, in reduced CIP-susceptible *S*. typhi, S83F and D87Y usually existed. Moreover, coexisting *gyrA* mutation and one or two PMQR genes were found in a number of reduced CIP-susceptible isolates, inconsistent with the previous statement that this coexistence is rare.[@b25-idr-11-267] To conclude, prevalence of *qnrB* and *aac(6′)-Ib-cr* is significantly higher in CIP-resistant isolates, whereas *gyr* mutations in several CIP-resistant isolates ([Table 4](#t4-idr-11-267){ref-type="table"}). Although it is usually believed that CIP resistance is mainly due to *gyrA* mutations[@b28-idr-11-267] and PMQR genes cause low-level resistance to CIP in enteric bacteria,[@b29-idr-11-267] our results demonstrate that it is not always the case in *Salmonella*. Given that it is difficult to obtain a large number of CIP-resistant isolates, we hope there will be more future studies to increase knowledge in this field. In addition, in highly CIP-resistant isolates (Kentucky and Indiana with MIC \>16 μg/mL), presence of two *gyrA* mutations plus *qnrB* and/or *aac(6*′*)-Ib-cr* is common.

Conclusion
==========

Our study shows that in *Salmonella*, there exists a high prevalence of reduced CIP susceptibility and a low prevalence of CIP resistance in limited serotypes. The CIP-resistant isolates generally show concurrent resistance to β-lactams. Our study also demonstrates that, rather than *gyrA* mutations, PMQR gene *qnrB* is the most common indicator for CIP resistance.
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###### 

Distribution of *Salmonella* isolates by isolation year and their susceptibility to CIP

  Serotype                                                 Resistance level   Number of isolates   Total         
  -------------------------------------------------------- ------------------ -------------------- ------- ----- -------
  *S*. typhi (n=188)                                       Susceptibility     49                   39      8     96
  Reduced CIP susceptibility                               5                  21                   66      92    
  CIP resistance                                           --                 --                   --      --    
  *S*. Enteritidis (n=163)                                 Susceptibility     16                   32      17    65
  Reduced CIP susceptibility                               23                 41                   34      98    
  CIP resistance                                           --                 --                   --      --    
  *S*. Typhimurium (n=156)                                 Susceptibility     22                   28      39    89
  Reduced CIP susceptibility                               17                 16                   27      60    
  CIP resistance                                           --                 2                    5       7     
  Other serotypes (48 serotypes and untypeable; n=1,269)   Susceptibility     220                  286     472   978
  Reduced CIP susceptibility                               36                 71                   165     272   
  CIP resistance                                           1                  4                    14      19    
  Total                                                                       389                  540     847   1,776

**Abbreviations:** CIP, ciprofloxacin; *S*. typhi; *Salmonella* Typhi; *S*. Enteritidis, *Salmonella* Enteritidis; *S*. Typhimurium, *Salmonella* Typhimurium.

###### 

Primers used for amplifying genes related to quinolone and β-lactam resistance

  Gene                                   Primers (5′→3′)                           Amplicon size (bp)   Reference
  -------------------------------------- ----------------------------------------- -------------------- -------------------
  **For mutations in QRDR**                                                                             [@b17-idr-11-267]
  *gyrA*                                 gyrA-1: CGTTGGTGACGTAATCGGTA              251                  
  gyrA-2: CCGTACCGTCATAGTTATCC                                                                          
  *gyrB*                                 gyrB-1: GCGCTGTCCGAACTGTACCT                                   
  gyrB-2: TGATCAGCGTCGCCACTTCC                                                                          
  *parC*                                 parC-1: CTATGCGATGTCAGAGCTGG              270                  
  parC-2: TAACAGCAGCTCGGCGTATT                                                                          
  **For PMQR genes**                                                                                    [@b18-idr-11-267]
  *aac(6′)-Ib-cr*                        aac(6*′*)-Ib-1: TTGCGATGCTCTATGAGTGGCTA   482                  
  aac(6*′*)-Ib-2: CTCGAATGCCTGGCGTGTTT                                                                  
  *qnrA*                                 qnrA-1: TCAGCAAGAGGATTTCTCA               627                  
  qnrA-2: GGCAGCACTATTACTCCCA                                                                           
  *qnrB*                                 qnrB-1: GGMATHGAAATTCGCCACTG              264                  
  qnrB-2: TTTGCYGYYCGCCAGTCGAA                                                                          
  *qnrS*                                 qnrS-1: ATGGAAACCTACAATCATAC              467                  
  qnrS-2: AAAAACACCTCGACTTAAGT                                                                          
  *qepA*                                 qepA-1: GCAGGTCCAGCAGCGGGTAG              199                  
  qepA-2: CTTCCTGCCCGAGTATCGTG                                                                          
  **For b-lactam resistance genes**                                                                     This study
  *bla*~CTX-M14-like~                    CTX-M14-1: AAAACTTGCCGAATTAGAGC           711                  
  CTX-M14-2: TTAGGTTGAGGCTGGGTGAA                                                                       
  *bla*~CTX-M15-like~                    CTX-M15-1: ATGAACGCTTTCCAATGTGC           461                  
  CTX-M15-2: GGTCGTATTGCCTTTGAGCC                                                                       
  *bla*~OXA~                             OXA-1: AATGGCACCAGATTCAACTT               593                  
  OXA-2: TGGCTTTTATGCTTGATGTT                                                                           
  *bla*~TEM~                             TEM-1: TGTCGCCCTTATTCCCTTTT               783                  
  TEM-2: ATAGTTGCCTGACTCCCCGT                                                                           

**Abbreviations:** QRDR, quinolone resistance-determining region; PMQR, plasmid-mediated quinolone resistance.

###### 

Results of resistance to antimicrobials tested in isolates with different CIP susceptibilities

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antimicrobial                    Reduced CIP susceptible\                                                                          CIP resistant\                                         Susceptible\   Total (n=1,776)
                                   (n=522)                                                                                           (n=26)                                                 (n=1,228)      
  -------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------ -------------- -----------------
  Ampicillin                       210 (40.2[a](#tfn3-idr-11-267){ref-type="table-fn"})[\*](#tfn4-idr-11-267){ref-type="table-fn"}   26 (100)[\*](#tfn4-idr-11-267){ref-type="table-fn"}    365 (29.7)     601 (33.8)

  Cefotaxime                       13 (2.5)[\*](#tfn4-idr-11-267){ref-type="table-fn"}                                               15 (57.7)[\*](#tfn4-idr-11-267){ref-type="table-fn"}   5 (0.4)        33 (1.9)

  ESBL producing                   8 (1.5)[\*](#tfn4-idr-11-267){ref-type="table-fn"}                                                14 (53.8)[\*](#tfn4-idr-11-267){ref-type="table-fn"}   4 (0.3)        26 (1.5)

  Gentamicin                       50 (9.6)[\*](#tfn4-idr-11-267){ref-type="table-fn"}                                               8 (30.8)[\*](#tfn4-idr-11-267){ref-type="table-fn"}    84 (6.8)       142 (8.0)

  Chloramphenicol                  38 (7.3)                                                                                          20 (76.9)[\*](#tfn4-idr-11-267){ref-type="table-fn"}   67 (5.5)       125 (7.0)

  Trimethoprim--sulfamethoxazole   55 (10.5)[\*](#tfn4-idr-11-267){ref-type="table-fn"}                                              21 (80.8)[\*](#tfn4-idr-11-267){ref-type="table-fn"}   75 (6.1)       151 (8.5)

  Average resistance rate (%)      11.9[\*](#tfn4-idr-11-267){ref-type="table-fn"}                                                   66.7[\*](#tfn4-idr-11-267){ref-type="table-fn"}        8.1            10.1
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Percentage of number of resistant isolates to number of all isolates.

Statistically significant compared with group of susceptible isolates.

**Abbreviations:** CIP, ciprofloxacin; ESBL, extended-spectrum β-lactamase.

###### 

Serotype distribution, CIP MICs, topoisomerases and PMQR genes, and β-lactamase genes of 26 CIP-resistant isolates

  Serotypes     No. of isolates   Source (n)             MIC (μg/mL)   ESBL    *gyrA*   *parC*           PMQR   β-lactamase                         
  ------------- ----------------- ---------------------- ------------- ------- -------- ---------------- ------ ----------------------------------- ------------
  Indiana       6                 Water (4), feces (2)   \>32          \>128   Yes      S83F, D87N       S80R   *qnrB*, *aac(6′)-Ib-cr*             OXA, CTX-M
  Typhimurium   4                 Food (2), feces (2)    2--4          128     Yes      --               S80R   *qnrB*, *qnrS*                      CTX-M
  Typhimurium   2                 Feces (2)              2--4          64      Yes      D87N             WT     *qnrB*, *aac(6′)-Ib-cr*             OXA
  Agona         2                 Feces (1), food (1)    2--4          64      Yes      S(TCC)83S(TCT)   WT     *qnrB*                              TEM
  Derby         5                 Feces (5)              2             64      Yes      S(TCC)83S(TCT)   WT     *qnrB*, *qnrS*, *aac(6′)-Ib*-*cr*   OXA, TEM
  London        3                 Feces (3)              2             \<1     No       --               WT     *qnrB*, *aac(6′)-Ib-cr*             --
  Rissen        1                 Blood (1)              2             4       No       --               WT     *qnrB*                              TEM
  Corvallis     1                 Feces (1)              2             \<1     No       --               WT     *qnrB* + *qnrS*                     --
  Kentucky      1                 Food (1)               16            64      Yes      S83F, D87G       S80R   *qnrB*                              CTX-M
  Hadar         1                 Feces (1)              2             \<1     No       --               WT     *qnrB*                              --

**Abbreviations:** CIP, ciprofloxacin; MIC, minimal inhibitory concentration; PMQR, plasmid-mediated quinolone resistance; ESBL, extended-spectrum β-lactamase; WT, wild type.

###### 

Prevalence of genetic determinants related to quinolone resistance in CIP-resistant isolates and in 100 reduced CIP-susceptible isolates

  Gene                        Reduced CIP-susceptible isolates (n=100), %   CIP-resistant isolates (n=26), %                     *P*[a](#tfn7-idr-11-267){ref-type="table-fn"}
  ----------------- --------- --------------------------------------------- ---------------------------------------------------- -----------------------------------------------
  PMQR gene         *qnrA*    5 (5)                                         --                                                   --
  *qnrB*            --        26 (100)                                      \<0.001[\*](#tfn8-idr-11-267){ref-type="table-fn"}   
  *qnrS*            20 (20)   10 (38)                                       0.14                                                 
  *aac(6′)-Ib-cr*   15 (15)   16 (62)                                       \<0.001[\*](#tfn8-idr-11-267){ref-type="table-fn"}   
  *gyrA* mutation   S83F      8 (8)                                         7 (27)                                               --
  S(TCC)83S(TCT)    --        7 (27)                                        --                                                   
  D87N              6 (6)     8 (31)                                        --                                                   
  D87Y              4 (4)     --                                            --                                                   
  D87G              --        1 (4)                                         --                                                   
  Event/isolate     0.18      0.88                                          \<0.001[\*](#tfn8-idr-11-267){ref-type="table-fn"}   

**Notes:**

*P* value between reduced CIP-susceptible and CIP-resistant isolates.

Statistically significant.

**Abbreviations:** CIP, ciprofloxacin; PMQR, plasmid-mediated quinolone resistance.
